SPC
BIB icon

Sigma Planning Corp’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Sigma Planning Corp’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,090
Closed -$251K – 856
2017
Q3 		$251K Sell
4,090
-748
-15% -$42.5K 0.02% 678
2017
Q2 		$258K Sell
4,838
-2,079
-30% -$101K 0.02% 618
2017
Q1 		$334K Sell
6,917
-2,818
-29% -$131K 0.03% 535
2016
Q4 		$389K Buy
+9,735
New +$416K 0.04% 431

Other funds holding BIB

OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return

Sigma Planning Corp's BIB Position: Q4 2017 in Review

Sigma Planning Corp sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2017, closing a stake of 4,090 shares — an estimated $251K sold.

Sigma Planning Corp first reported a position in BIB in Q4 2016 and held it in 4 quarters. The position peaked at $389K in Q4 2016. 40 funds tracked by Wall St. Rank hold BIB as of Q4 2017.

  • Sigma Planning Corp reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2017 after selling out during the quarter.
  • Sigma Planning Corp sold 4,090 ProShares Ultra NASDAQ Biotechnology shares in Q4 2017, an estimated $251K.
  • Sigma Planning Corp first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2016 and held it in 4 quarters.
  • Sigma Planning Corp's ProShares Ultra NASDAQ Biotechnology position peaked at $389K in Q4 2016.
  • 40 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2017.

Based on Sigma Planning Corp's 13F filing for Q4 2017, filed 7 Feb 2018.